Multi-pathway cholesterol depletion on top of FOLFIRINOX in newly diagnosed metastatic pancreatic adenocarcinoma: a feasibility and proof-of-concept study

在新诊断的转移性胰腺腺癌中使用 FOLFIRINOX 进行多途径胆固醇消耗：可行性和概念验证研究

• 批准号: 402794
• 负责人: Gangloff Anne
• 金额: $ 11.15万
• 依托单位: CHU de Qubec
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-03-01 至 2021-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=402794&lang=en
• 关键词: Acceptability Of The Regimen; Biomarkers (Lipid Profile, Tumoral Ldlr, Npc1l1, Srb1); Cholesterol-Lowering Drugs (Pcsk9 Inh, Statins, Ezetimibe); Clinical Trial (Non-Randomized, Open-Label); Dose-Limiting Toxicities; Estimates Of Progression-Free Survival; Acceptability Of The Regimen; Biomarkers (Lipid Profile, Tumoral Ldlr, Npc1l1, Srb1); Cholesterol-Lowering Drugs (Pcsk9 Inh, Statins, Ezetimibe); Clinical Trial (Non-Randomized, Open-Label); Dose-Limiting Toxicities; Estimates Of Progression-Free Survival

According to the Canadian Cancer Statistics, out of 100 patients diagnosed with pancreatic cancer, only 8 will still be alive 5 years later. Most patients will die within the first year after diagnosis. Given this very poor survival, there is an urgent ne

根据加拿大癌症统计数据，在诊断出患有胰腺癌的100名患者中，只有8年仍将活着5年。大多数患者将在诊断后的第一年内死亡。鉴于这个非常差的生存，有一个紧急的新